Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis (NCT04888546) | Chinese Academy of Medical Sciences | 2021-04-30 |
Track Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi automatically
Every clearance here is in the API, with alerts when new ones post.